News >

Larotrectinib Rolling NDA Submission Initiated for TRK+ Cancers

Jason Harris
Published: Wednesday, Dec 20, 2017

 Josh Bilenker, MD

Josh Bilenker, MD
Loxo Oncology has initiated a rolling submission of data for a new drug application (NDA) to the FDA for the novel pan-TRK inhibitor larotrectinib (LOXO-101) as a treatment for adult and pediatric patients with TRK fusion-positive advanced solid tumors.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x